Download PDF
Nervenheilkunde 2014; 33(09): 601-608
DOI: 10.1055/s-0038-1627719
Psychopathologie
Schattauer GmbH

Zur Bedeutung der experimentellen Psychosenforschung in der Psychiatrie

Significance of experimental psychosis research in psychiatry
L. Hermle
1   Klinik für Psychiatrie und Psychotherapie “Christophsbad”, Göppingen
,
M. Geppert
1   Klinik für Psychiatrie und Psychotherapie “Christophsbad”, Göppingen
› Author Affiliations
Further Information

Publication History

eingegangen am: 20 April 2014

angenommen am: 28 April 2014

Publication Date:
24 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Experimentelle Psychopathologie zielt primär auf nosologieübergreifende Funktionsstörungen psychoneurobiologisch definierter Systeme, die bei ähnlichen Syndromen im Rahmen nosologischer Entitäten vorkommen können. Entsprechend dem Vulnerabilitätsmodell muss der Bezugsrahmen der Forschung mit dem Modellpsychosenparadigma über die nosologischen Entitäten, z. B. der Schizophrenie, hinausgehen. Experimentelle Studien mit psychoaktiven Substanzen bei gesunden Probanden bieten im Vergleich mit Studien bei schizophrenen Patienten im Hinblick auf die standardisierbaren Versuchsbedingungen viele Vorteile. Sorgfältig geplante Untersuchungen mit Hilfe des Modellpsychosenparadigmas sind ein Schritt in Richtung einer symptomorientierten Forschung. Im Hinblick auf die differenzierten psychologischen und neurobiologischen Untersuchungsmöglichkeiten stellt der traditionelle Ansatz der experimentellen Psychosen ein für die Psychiatrie wertvolles Forschungsinstrument dar.

Summary

The aim of experimental psychopathology is to delineate overlapping functional disorders of psychoneurobiologically defined systems where a set of common symptoms may correspond to a variety of nosological entities. According to the vulnerability model of psychosis, experimental research needs to go beyond categories such as “schizophrenia”. Prospective studies of the effects of psychoactive substances in normal control subjects offer several methodological advantages over routine clinical reviews of schizophrenic patients, especially in terms of standardization. Carefully designed studies utilizing a model psychosis paradigm are a step towards symptom-oriented research. Combining psychological and neurobiological techniques, the experimental psychopathological approach can provide us with a valuable tool for psychiatric research.

Schlüsselwörter

Experimentelle Psychopathologie - Halluzinogen induzierte Modellpsychose

Keywords

Experimental psychopathology - hallucinogen induced model psychosis
 

  • Literatur

  • 1 Scharfetter C. Schizophrene Menschen. München: Psychologie Verlags Union, Urban & Schwarzenberg. 1990
    PubMedGoogle Scholar
  • 2 Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences 2008; 29 (09) 445-453.
    CrossrefPubMedGoogle Scholar
  • 3 Marek GJ, Aghajanian GK. Indolamine and the phenethylamine hallucinogens: Mechanisms of psychotomimetic action. Drug and Alcohol Dependence. 1998. 51(1–2): 189-198.
    Google Scholar
  • 4 Pechnik RN. et al. In: Lowinson JH. et al. (eds). Substance abuse: a comprehensive textbook. 4th edition,. Baltimore: Lippincott Williams & Wilkins; 2004: 313-323.
    Google Scholar
  • 5 Hermle L. et al. Halluzinogen-induzierte psychische Störungen. Fortschr Neurol Psychiat 2008; 76 (06) 334-342.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Nichols D. Hallucinogens. Pharmacology & Therapeutics 2004; 101 (02) 131-181.
    CrossrefPubMedGoogle Scholar
  • 7 Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience. 2010 online; doi:10.1038/nrn2884.
    PubMedGoogle Scholar
  • 8 Vollenweider FX. Neurobiologie der Halluzinogenerfahrung. In: Therapie mit psychoaktiven Substanzen. In: Jungaberle H. et al. (Hrsg.). Bern: Huber; 2008: 111-129.
    Google Scholar
  • 9 Kowalewsky P. Atropin-Psychose. Allg Z Psychiat 1880; 36: 431.
    Google Scholar
  • 10 Heffter A. Über Cacteenalkaloide. Berichte der Deutschen Chemischen Gesellschaft 1898; 31: 1193.
    CrossrefGoogle Scholar
  • 11 Spaeth E. Über die Anhalonium-Alkaloide. Anhalin und Mescalin. Monatshefte Chemie 1919; 40: 129.
    Google Scholar
  • 12 Knauer A, Maloney WJ. A preliminary note on the psychic action of mescaline with special refererence to the mechanisms of visual hallucinations. J Nerv Ment Dis 1913; 40: 425-436.
    Google Scholar
  • 13 Beringer K. Der Meskalinrausch. Seine Geschichte und Erscheinungsweise. Monograph. Neurol Psychiatr H 49. Heidelberg: Springer; 1927
    Google Scholar
  • 14 Beringer K. Die Bedeutung der Rauschgiftversuche für die Klinik. Schweiz Arch Neurol 1932; 28: 1-17.
    Google Scholar
  • 15 Stoll WA. Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiat 1947; 60: 1-45.
    Google Scholar
  • 16 Rapport MM. Serum vasoconstrictor, serotonin, chemical inactivation. J Biol Chem 1948; 176: 1237-1241.
    PubMedGoogle Scholar
  • 17 Busciano GA. Panorami di biochimica topografia del sistema nervoso. Quaderno Acta Neurol Napoli. 1950
    PubMedGoogle Scholar
  • 18 Osmond H. Smythies JR. Schizophrenia, a new approach. J Ment Sci 1952; 98: 309.
    PubMedGoogle Scholar
  • 19 Gaddum IH. et al. Quantitative studies of antagonists for 5-hydroxytryptamine. Quard J Exp Phisiol 1955; 40: 49.
    Google Scholar
  • 20 Shaw E, Woolley DW. Some serotoninlike activities of lysergic acid diethylamide. Science 1956; 124: 121-122.
    CrossrefPubMedGoogle Scholar
  • 21 Leary T, Metzner R, Alpert R. The psychedelic experience. A manual based on the tibetan book of the dead. New York: Univ. books; 1964
    Google Scholar
  • 22 Dittrich A. Ätiologie-unabhängige Strukturen veränderter Wachbewußtseinszustände. Stuttgart: Enke; 1985
    Google Scholar
  • 23 Strassman RJ. et al. Dose reponse study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994; 51: 98-108.
    PubMedGoogle Scholar
  • 24 Vollenweider FX. Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichigung der Ketamin/PCPModellpsychose. Sucht 1992; 38: 398-409.
    Google Scholar
  • 25 Hermle L. et al. Mescaline-induced psychopathological, neuropsychological and neurometabolic effects in male volunteers. Experimental psychosis as a tool for psychiatric research. Biological Psychiatry 1992; 32: 976-991.
    PubMedGoogle Scholar
  • 26 Hermle L. et al. Psychological effects of MDE in normal subjects: Are entactogens a new class of psychoactive agents?. Neuropsychopharmacology 1993; 08: 171-176.
    CrossrefPubMedGoogle Scholar
  • 27 Spitzer M. et al. Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology 2001; 41: 263-271.
    CrossrefPubMedGoogle Scholar
  • 28 Gouzoulis-Mayfrank E. et al. Hallucinogenic drug induced states resemble acute endogenous psychoses. Results of an empirical study. Eur Psychiatry 1998; 13: 399-406.
    PubMedGoogle Scholar
  • 29 Gouzoulis-Mayfrank E. et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxy-ethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double blind placebo-controlled study. Psychopharmacology 1999; 142: 41-50.
    PubMedGoogle Scholar
  • 30 Gouzoulis-Mayfrank E. et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999; 20: 565-581.
    PubMedGoogle Scholar
  • 31 Vollenweider FX. et al. Positron emission tomographyand fluorodeoxyglucose studies of metabolic hyperfontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 1997; 16: 357-372.
    PubMedGoogle Scholar
  • 32 Vollenweider FX. et al. Psilocybin induces schizophrenia-like psychosis in humans via serotonin-2 agonist action. Neuroreport 1998; 08: 3897-3902.
    Google Scholar
  • 33 Marona-Lewicka D, Thisted RA, Nichols DE. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2-receptor mediated effects in the rat and implications for psychosis. Psychopharmacology (Berlin) 2005; 180 (03) 427-435.
    CrossrefPubMedGoogle Scholar
  • 34 Lambe EK, Aghajanian GK. Hallucinogen-induced UP statesin the brain slice of rat prefrontal cortex: role of glutamate spillover and NR2B-NMDA receptors. Neuropsychopharmacology 2006; 31 (08) 1682-1689.
    CrossrefPubMedGoogle Scholar
  • 35 Conrad K. Die beginnende Schizophrenie. Stuttgart: Thieme; 1958
    Google Scholar
  • 36 Janzarik W. Strukturdynamische Grundkonstellationen in endogenen Psychosen. Heidelberg: Springer; 1959
    Google Scholar
  • 37 Faillace LA, Vourlekis A, Szara S. Cinical evaluation of some hallucinogenic trytamine derivates. J Nerv Ment Dis 1967; 145: 306-313.
    CrossrefPubMedGoogle Scholar
  • 38 Sessa B. Can psychedelics have a role in psychiatry again?. British J Psychiatry 2005; 186: 457-458.
    CrossrefPubMedGoogle Scholar
  • 39 Studerus E. et al. Acute, subacute and long-term sujective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmaology. 2010 DOI: 10.1177/02698811 10382466.
    PubMedGoogle Scholar